Quantum BioPharma Ltd. (QNTM) - Net Assets
Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) has net assets worth $7.51 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.15 Million) and total liabilities ($6.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Quantum BioPharma Ltd. to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.51 Million |
| % of Total Assets | 53.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | -71.25% |
| 10-Year Change | N/A |
| Growth Volatility | 107.01 |
Quantum BioPharma Ltd. - Net Assets Trend (2015–2024)
This chart illustrates how Quantum BioPharma Ltd.'s net assets have evolved over time, based on quarterly financial data. See how many days can Quantum BioPharma Ltd. fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Quantum BioPharma Ltd. (2015–2024)
The table below shows the annual net assets of Quantum BioPharma Ltd. from 2015 to 2024. For live valuation and market cap data, see Quantum BioPharma Ltd. (QNTM) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $10.44 Million | -19.13% |
| 2023-12-31 | $12.91 Million | -57.73% |
| 2022-12-31 | $30.54 Million | -43.58% |
| 2021-12-31 | $54.13 Million | +49.09% |
| 2020-12-31 | $36.31 Million | +0.09% |
| 2019-12-31 | $36.28 Million | -3.18% |
| 2018-12-31 | $37.47 Million | +279.55% |
| 2017-12-31 | $9.87 Million | +18281.03% |
| 2016-12-31 | $-54.30K | +6.98% |
| 2015-12-31 | $-58.37K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Quantum BioPharma Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17085448122.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $150.47 Million | 1310.66% |
| Other Comprehensive Income | $50.80K | 0.44% |
| Other Components | $33.07 Million | 288.06% |
| Total Equity | $11.48 Million | 100.00% |
Quantum BioPharma Ltd. Competitors by Market Cap
The table below lists competitors of Quantum BioPharma Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Herkules S.A.
WAR:HRS
|
$13.99 Million |
|
Star Diamond Corp
TO:DIAM
|
$14.00 Million |
|
Golden Land Bhd
KLSE:7382
|
$14.00 Million |
|
KIWI Media Group Co.Ltd
KO:012170
|
$14.02 Million |
|
Vesuvius PLC
LSE:VSVS
|
$13.97 Million |
|
Samil Co.Ltd
KQ:032280
|
$13.97 Million |
|
Les Hôtels de Paris SA
PA:HDP
|
$13.96 Million |
|
Aco Group Bhd
KLSE:0218
|
$13.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Quantum BioPharma Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,236,763 to 11,480,538, a change of -1,756,225 (-13.3%).
- Net loss of 14,202,724 reduced equity.
- New share issuances of 10,670,618 increased equity.
- Other comprehensive income decreased equity by 366,546.
- Other factors increased equity by 2,142,427.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.20 Million | -123.71% |
| Share Issuances | $10.67 Million | +92.95% |
| Other Comprehensive Income | $-366.55K | -3.19% |
| Other Changes | $2.14 Million | +18.66% |
| Total Change | $- | -13.27% |
Book Value vs Market Value Analysis
This analysis compares Quantum BioPharma Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.39x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-0.58 | $3.97 | x |
| 2016-12-31 | $-0.54 | $3.97 | x |
| 2017-12-31 | $97.74 | $3.97 | x |
| 2018-12-31 | $412.42 | $3.97 | x |
| 2019-12-31 | $334.18 | $3.97 | x |
| 2020-12-31 | $195.95 | $3.97 | x |
| 2021-12-31 | $100.69 | $3.97 | x |
| 2022-12-31 | $51.26 | $3.97 | x |
| 2023-12-31 | $21.73 | $3.97 | x |
| 2024-12-31 | $10.10 | $3.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Quantum BioPharma Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -123.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.49x
- Recent ROE (-123.71%) is below the historical average (-66.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.96K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.20K |
| 2017 | -28.39% | -13586.02% | 0.00x | 1.10x | $-3.79 Million |
| 2018 | -44.50% | 0.00% | 0.00x | 1.03x | $-20.42 Million |
| 2019 | -107.86% | 0.00% | 0.00x | 1.19x | $-42.76 Million |
| 2020 | -87.58% | 0.00% | 0.00x | 1.16x | $-35.43 Million |
| 2021 | -65.19% | 0.00% | 0.00x | 1.16x | $-40.70 Million |
| 2022 | -77.29% | 0.00% | 0.00x | 1.26x | $-26.66 Million |
| 2023 | -135.25% | 0.00% | 0.00x | 1.32x | $-19.23 Million |
| 2024 | -123.71% | 0.00% | 0.00x | 1.49x | $-15.35 Million |
Industry Comparison
This section compares Quantum BioPharma Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Quantum BioPharma Ltd. (QNTM) | $7.51 Million | 0.00% | 0.89x | $13.99 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more